🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PPCB PPCB

Company Profile ↓
$1.18
-99.48% 1Y
Mkt Cap$548.08K
P/E-0.08
P/B-0.15
52W High$260.00
52W Low$0.99
Book Value$-8.14
EPS (TTM)$-14.85

Company Overview

PPCB (PPCB) is a publicly traded company listed on with a market capitalization of $548.08K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 48.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 41.3%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Growth & Price Performance

Stock Price Performance

1 Year:-99.48%
6 Months:-78.55%
3 Months:-54.04%
1 Month:-35.16%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.99 $260.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)40.88 · Neutral
Price Performance
1M-35.16%
3M-54.04%
6M-78.55%
1Y-99.48%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 48.2%.
  • Healthy ROCE of 41.3%.

CONS

  • Trading 99.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.08
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-8.14
Price to Book
-0.15
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
41.29%
ROE
48.17%
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-7.00
EPS (TTM)
$-14.85

Balance Sheet & Liquidity

Debt/Equity
0.05
Quick Ratio
-
Current Ratio
0.01
Debt
$948.27K
Total Assets
$14.33M
Current Assets
$8.22M
Working Capital
$-3.77M

Ownership

Promoter Holding
45.13%
Chg in Prom Hold
0.00%
FII / Inst Holding
0.81%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-1.26M
Free Cash Flow
$-935.12K
Operating Cash Flow
$-935.12K
Shares Outstanding
464.47K
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Sep 2013Dec 2013Mar 2014Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Sep 2017Dec 2017Mar 2018Sep 2018Dec 2018Mar 2019Sep 2019Dec 2019Mar 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue -----------------------------------00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------213.38K53.13M4.67M3.65M6.40M
Operating Income -229.37K-308.57K-225.45K-104.31K-238.14K-249.44K-516.57K-1.01M-1.14M-1.29M-1.17M-1.91M-1.55M-1.20M-1.44M-807.13K-448.87K-757.82K-571.73K-909.42K-1.38M-607.17K-383.16K-274.09K-427.95K-486.03K-403.47K-502.18K-572.83K-608.00K-386.21K-417.22K-438.06K-420.87K-290.79K-213.38K-53.13M-4.67M-3.65M-6.40M
EBITDA ------------------------------------306.91K-53.96M-4.53M-3.03M-6.32M
Interest Expense -----------------------------------118.94K104.04K305.65K58.95K38.27K
Pretax Income ------------------------------------430.18K-54.07M-4.84M-3.09M-6.36M
Tax Provision -----------------------------------00000
Net Income -337.67K-571.51K26.40K-66.86K-783.30K-345.48K-454.25K-838.89K-3.56M-2.15M-1.10M-3.76M-1.37M-1.92M-2.20M-1.49M-2.12M-1.45M-581.86K-1.49M-1.87M-2.59M-425.55K-403.64K-417.74K-490.66K-799.98K-462.69K-617.29K-485.42K-809.81K-350.87K-584.38K-526.70K-354.31K-430.18K-54.07M-4.84M-3.09M-6.36M
Diluted EPS -----------------------------2.13-0.53-0.42-0.04-1,559.55-545.79-35.97-32.23-12.50-0.39-0.30-7.00
R&D Expense -0003.88K2.44K9.47K153.47K142.80K510.30K161.20K167.20K386.49K563.74K1.03M75.14K56.19K94.78K52.66K65.37K3757.48K50.85K50.16K44.89K46.55K50.75K50.40K101.33K74.88K66.02K16.24K114.02K65.45K61.71K54.39K54.10K60.20K19.96K169.66K

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue -------------000-
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------1.99M1.78M1.54M-
Operating Income ---2.24M-11.59M-1.36M-761.22K-1.71M-6.90M-5.74M-3.96M-2.61M-3.49M-1.81M-1.99M-1.78M-1.54M-
EBITDA --------------2.14M-2.23M-1.26M-
Interest Expense -------------568.80K532.82K665.84K-
Pretax Income --------------2.71M-2.79M-1.95M-
Tax Provision --------------54.98K-129.84K-129.13K-
Net Income -443.85K-842.49K-2.15M-11.43M-1.44M-829.56K-3.41M-9.41M-7.87M-7.04M-5.76M-4.74M-2.03M-2.66M-2.66M-1.82M-
Diluted EPS --------------1,119,475.67-781,709.75-1,420.53-14.85
R&D Expense --385.78K5.28K12.34K8.17K134.32K1.45M971.77K1.83M260.33K179.99K230.96K256.05K247.92K248.10K223.72K

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets ---10.81M46.27K1.75K113.75K627.07K379.14K95.07K71.39K101.65K98.52K13.10K81.65K60.33K72.36K-
Current Assets --------------15.03K19.04K25.44K-
Cash & Equivalents ---132179087.80K-----67.01K2.25K4.07K10.05K21.09K-
Inventory ------------------
Receivables --------------2.34K2.87K2.95K-
Total Liabilities ---306.85K584.19K------4.40M3.74M3.08M3.11M3.18M3.85M-
Current Liabilities ---306.85K584.19K794.22K1.52M3.68M2.94M5.54M6.82M4.40M3.74M3.08M3.06M3.16M3.79M-
Long Term Debt --------1.20M3.48M4.70M1.66M1.56M624.58K--58.64K-
Total Debt --------------1.04M545.92K948.27K-
Total Equity 85.13K-409.39K-186.90K10.51M-537.92K-792.48K-1.41M-3.05M-2.57M-5.44M-6.75M-4.30M-3.64M-3.07M-3.02M-3.12M-3.78M-
Shares Outstanding --------------34319464.47K

Cash Flows (Annual)

Figures in USD.

Metric Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow -1.40M-170.28K-128.65K226.44K---2.05M-2.18M-2.06M-1.85M-1.15M-1.44M-1.11M-935.12K-
Investing Cash Flow -29.23K--0-5.58K----2.87K------
Financing Cash Flow 1.42M170.33K128.47K---2.10M2.40M2.12M1.89M1.06M1.49M1.11M941.89K-
Capital Expenditure -3.51K---0-3.90K-9.88K---2.87K------
Free Cash Flow -1.40M--226.44K-----2.06M---1.44M-1.11M-935.12K-
Net Change in Cash -----------54.48K8.47K6.78K-

Ratios (Annual)

Figures in %.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % -----------------
Operating Margin % -----------------
Net Margin % -----------------
ROE % 108.4%450.8%-20.5%2,125.7%182.0%58.9%111.8%366.8%144.6%104.3%133.9%130.2%66.0%87.9%85.4%48.2%-
ROCE % ---21.3%2,154.6%171.9%54.1%55.9%268.9%105.5%58.6%60.8%96.0%59.1%66.8%57.3%41.3%-

Shareholding Pattern

Insiders
45.13%
Institutions
0.81%
Public Float
1.48%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PPCB

Yahoo Finance Wed, 05 Aug 2026

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Purchasing $500,000 within First 30 days Since Program CommencementMELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developin…

Yahoo Finance ue, 21 Jul 2026

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

A Promising Strategy for Improving Production for Applications in Biotechnology ResearchMELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company…

Yahoo Finance ue, 07 Jul 2026

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRPMELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical co…

Yahoo Finance hu, 02 Jul 2026

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day periodMELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focu…

Yahoo Finance ue, 16 Jun 2026

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Pre-production, Engineering Run and GMP Manufacture of PRP in 2026MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing…

Yahoo Finance hu, 11 Jun 2026

PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?

Propanc Biopharma announced the approval of a share buyback program worth up to $5 million.

PPCB — Frequently Asked Questions

What is the current share price of PPCB?

As of 2026-08-05 17:25 PDT, PPCB trades at $1.18 on NASDAQ/NYSE. Its 52-week range is $0.99 to $260.00.

What is the market capitalisation of PPCB?

PPCB has a market capitalisation of $548.08K on NASDAQ/NYSE.

What is the P/E ratio of PPCB?

PPCB trades at a trailing price-to-earnings (P/E) ratio of -0.08. Its price-to-book (P/B) ratio is -0.15.

What is the return on equity (ROE) of PPCB?

PPCB has a return on equity (ROE) of 48.17%. Its return on capital employed (ROCE) is 41.29%.

Is PPCB a good stock to buy?

This page provides a data-driven analysis of PPCB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space